cfDNA
Cell-free DNA consists of DNA fragments outside intact cells. Tumor-associated alterations in those fragments can provide genomic information.
- Sequence alterations
- Copy number and chromosomal findings
- Genomic context for interpretation
cfDNA + cfRNA Liquid Biopsy for Blood Cancers
Understand the disease that remains.
Integrate circulating genomic, RNA and clonality insights for a broader molecular view of hematologic disease.

In hematologic disease, an integrated molecular profile can bring together circulating genomic findings, RNA expression and clonality information. These complementary perspectives support a broader assessment than an isolated mutation or clonotype alone.
Cell-free DNA consists of DNA fragments outside intact cells. Tumor-associated alterations in those fragments can provide genomic information.
Cell-free RNA adds information about gene messages. It can contribute evidence about expressed fusions, gene expression and abnormal splicing.
RNA abundance and molecular shedding vary. The value of the combined profile comes from evaluating complementary findings together—not from assuming every sample contains every signal.
Review molecular evidence in the context of diagnosis, treatment history and the complete clinical workup.

Integrate mutations, chromosomal findings and RNA information with the clinical and pathology evaluation.

Consider B- and T-cell clonality alongside other disease-associated findings when evaluating serial samples.

Review relevant molecular biomarkers and CAR-T construct findings in the context of the patient’s therapy.
Conceptual scientific illustrations.
A clonality finding is one part of the disease profile. Mutations, fusions, expression and chromosomal findings provide additional information for integrated interpretation.
Compare results alongside treatment history, marrow findings, blood counts and other relevant studies. Clinical interpretation matters when a molecular signal persists or changes.
GTC’s current resources include CAR-T reporting. Construct detection adds a molecular observation; it does not by itself establish that the cells remain functional or that treatment is effective.
Peripheral blood and bone marrow answer different questions. Liquid biopsy may contribute useful information, while marrow or tissue evaluation can remain necessary for diagnosis and management.
Combine a clonality finding with broader molecular context.
Review mutation, fusion and expression findings alongside longitudinal results.
Bring CAR-T construct information into the broader molecular discussion.



Select a scene to explore the story. These are conceptual visuals, not patient results.
| Measure | What it describes | How to read it |
|---|---|---|
| Variant allele frequency (VAF) | The fraction of assessed DNA molecules carrying a particular variant. | A relative molecular measure. Interpret it alongside sample composition and the variant’s clinical context. |
| Tumor load | A quantitative molecular signal, reported as mutant molecules per unit volume when applicable. | A concentration-based measure for comparison in an appropriate longitudinal setting, rather than a direct measurement of tumor size. |
Confirm the quantitative metrics applicable to the specimen and report with GTC.
Your doctor may use cell-free DNA and RNA in a blood sample to add information about a blood cancer. Results are interpreted with your other laboratory and clinical findings.
Possibly. Liquid biopsy and bone marrow testing answer different questions. Your doctor will explain which tests are needed.
The test may inform treatment discussions, but a treatment match is not guaranteed. Your doctor will explain what the findings mean for you.
A negative result does not rule out cancer. Your care team will consider other test results and whether further evaluation is needed.
Testing is ordered through your treating clinician. Discuss suitability and collection with your care team.
A clear path from selecting the test to submitting the specimen.
Choose Liquid Trace® Hematology and complete the requisition.
The clinical team selects and collects an appropriate specimen.
Include relevant clinical information and follow GTC’s shipping instructions.
Submit 10 mL peripheral blood in an EDTA tube. Coordinate collection, labeling, packaging and prompt shipment with the submitting team and GTC.
Get collection instructions and help choosing the right test.
Liquid Trace evaluates cfDNA and cfRNA. RNA contributes gene-message information that complements the genomic findings from DNA.
No single test answers every clinical question. The treating team may use liquid biopsy with tissue pathology, imaging and other studies.
Contact GTC to confirm the current turnaround time for the selected assay, specimen and clinical circumstances.
Use GTC’s ordering resources or call 866-484-8870. Patients should work with their treating clinician.
Discuss the right specimen and test for the clinical question.